drugset
drugset / Trial / NCT02080416

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

NCT02080416 ↗

Phase 0 Terminated 1 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NaSingle-groupOpen-labelTreatment

Summary

The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.

Timeline

Start
2014-07
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelfinavir Other / unclassified 3000 mg Oral

Indications

Castleman disease Epstein-Barr virus infection Hodgkins lymphoma Kaposi's sarcoma gastric cancer nasopharyngeal carcinoma non-Hodgkin lymphoma